If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
362
results.
Updated on
25/10/2026 [08:00:00]
Results 250 to 275 of 362
Absstract of: US20260266808A1
The present invention is directed to assay methods and compounds and kits used in such assays.
Absstract of: US20260265806A1
Embodiments of the instant disclosure relate to early diagnosis and intervention and/or treatment of neurodegenerative disorders and/or brain damage due to normal aging. Certain embodiments disclosed herein relate to quantifying concentrations of ubiquitin c-terminal hydrolase L1 (UCH-L1) in samples obtained from a subject to assess neuronal cell health and/or diagnose the subject with age-related neuronal cell damage. In some embodiments, a subject can be treated with an effective amount of a therapeutic to stabilize and/or reduce concentrations of UCH-L1 in the subject and treat the subject. In other embodiment, a targeted therapeutic agent, process, or task can be assessed for efficacy of reversing brain aging in a subject.
Absstract of: AU2026204971A1
The present disclosure generally relates to a cell culturing system, and specifically to a three-dimensional cell culturing system for neuronal cells that promotes both structural and functional characteristics that mimic those of in vivo peripheral fibers, including cell myelination. Using a dual hydrogel construct and spheroids comprising neuronal cells, the present disclosure provides methods, devices, and systems for in vitro spatially-controlled, three-dimensional models that permit intra- and extra-cellular electrophysiological measurements and recordings. The three-dimensional hydrogel constructs allow for flexibility in incorporated cell types, geometric fabrication, and electrical manipulation, providing viable systems for culture, perturbation, and testing of biomimetic neural growth with physiologically-relevant results. BSTRACT
Absstract of: US20260266850A1
0000 Methods, compositions and kits useful in the detection, assessment, diagnosis, prognosis and/or treatment of neurological injury or disease or brain injury, such as traumatic brain injury (TBI), are provided in which certain newly discovered protein biomarkers are detected in a biological sample of a subject undergoing testing or evaluation. The methods allow for detection of changes in levels, amounts, or concentrations of the protein biomarkers in a subject compared with those of controls. Detection of the protein biomarkers, and/or levels thereof, provides an indication of biological and biochemical events, e.g., at a cellular level, that are occurring in the subject who is undergoing testing or analysis for the neurological injury or brain injury.
Absstract of: US20260265365A1
The present disclosure relates to anti-interleukin-11 (IL-11) antibodies and antigen-binding fragments thereof including their use in the treatment or prevention of an IL-11 (interleukin 11) pathway disease or disorder.
Absstract of: US20260266834A1
0000 A method for detecting proteins and/or their proteoforms is provided herein that includes adding one or more small molecule and one or more protein-binding agent to a biological sample, where a protein corona is formed on the surface of the protein-binding agent, and the proteins and/or their proteoforms in the protein corona are detected by an antibody-based technique or a proteomics technique. Also provided herein is a method for detecting one or more biomarker or a pattern of one or more biomarker associated with a disease or health spectrum condition, as well as a method of diagnosing or predicting a disease in a subject. Compositions including one or more small molecule, one or more protein-binding agent, and one or more biological sample are also provided.
Absstract of: US20260266724A1
An apparatus and method for identifying a protein or proteins in a sample of a biofluid. The identification is based on illuminating the sample with ultraviolet radiation and detecting and analyzing the resulting fluorescence. A trained model may be used to determine a protein responsible for a spectra detected from the illumination of the sample.
Absstract of: US20260266848A1
0000 Disclosed herein are compositions, kits, and methods for identifying protein, miRNA, or metabolite biomarkers for dystonia, for treating a subject having a dystonia, for selecting a subject for a clinical trial, for selecting a therapeutic agent, for treatment of dystonia in a subject, for classifying a subject having dystonia, and for predicting responsiveness to a dystonia treatment.
Absstract of: AU2025223493A1
The present disclosure provides nucleic acids, compositions, and methods of preventing or treating neurodegenerative disease in a subject comprising administering to the subject an agent that targets CHMP2B. In some embodiments the present disclosure provides a method of preventing or decreasing nuclear accumulation of CHMP7 in a cell comprising contacting the cell with an agent that targets expression of CHMP2B in the cell.
Absstract of: US20260265825A1
0000 A signature for identifying a subject at risk of developing a severe reaction to a SARS-CoV virus by detecting one or more of elevated serum cytokines, reduced monocyte subclasses, differentially expressed genes in monocyte subclasses, differentially expressed gene in CD8+ effector memory T cells, and elevated chromatin accessibility in intermediate monocytes are disclosed herein. Also disclosed are methods for obtaining the signature, methods of identifying a subject at risk of developing a severe reaction to a SARS-CoV virus, and methods of treating COVID-19.
Absstract of: WO2026188004A1
Provided are methods for determining the risk or monitoring the progression of Alzheimer's disease in a subject using expression levels of one or more circRNAs. Also provided are methods for treating a subject identified as having or at risk for Alzheimer's disease.
Absstract of: US20260265322A1
0000 Disclosed herein include polynucleotides, expression vectors and compositions enabling expression of a self-assembling proteopathic fusion protein comprising a self-assembling domain fused to a proteopathic polypeptide associated with a proteinopathy. The self-assembling proteopathic fusion protein is capable of forming intracellular protein aggregates that enable robust recapitulation of disease pathology. Provided herein also include methods of using the self-assembling systems disclosed herein to induce proteinopathies (e.g., neurodegenerative diseases) and to screen therapeutic compounds for the treatment of proteinopathies.
Absstract of: WO2026187918A1
Provided herein are systems, devices and methods relating to the diagnosis of traumatic brain injury. A mobile application uses a smartphone camera and an on-device artificial intelligence model to read lateral flow assay test strips and produce a concussion diagnostic result. The application determines whether a concussion biomarker is present in a sample and, when present, calculates a numeric intensity score that reflects the strength of the biomarker signal. Before displaying any result, the application automatically checks the image and test for a set of quality and validity conditions and, if any problem is found, tells the user specifically what went wrong and how to correct it. The application guides users through the entire testing process with a step-by-step interface designed to be usable without clinical training, stores all completed results on the device for longitudinal review, and can optionally receive data from a paired hardware lateral flow assay reader.
Absstract of: WO2026187110A1
The present invention relates to a method for customized diagnosis of patients with acyl coenzyme A overproduction and screening for therapeutic agents for acyl coenzyme A overproduction-associated diseases by using a metabolite having a nucleophilic amine group. The present invention provides a method capable of indirectly identifying the degree of acyl coenzyme A overproduction by measuring an acyl-product generated upon ingestion of a metabolite having a nucleophilic amine group, and thus enables customized diagnosis of patients with acyl coenzyme A overproduction and screening for customized therapeutic agents for diseases caused by acyl coenzyme A overproduction.
Absstract of: WO2026187868A1
The present disclosure provides specific anti-ac-tauK174, anti-ac-tauK274, and ac-tauK353 antibodies, or antigen-binding fragments thereof, and methods of their use in diagnosing, differentiating, targeting, staging, prognosing, and/or treating Alzheimer's Disease and related tauopathies, including traumatic brain injury. Methods of identifying a subject having early Alzheimer's Disease and related tauopathies are also provided, the methods comprising detecting proteins using at least one anti-ac-tauK174 antibody, at least one anti-ac-tauK274 antibody, and/or at least one anti-ac-tauK353 antibody. In some embodiments, the subject is ApoE4-positive.
Absstract of: AU2024395871A1
The present disclosure provides methods for simultaneously identifying dynamic and disease-associated RNA binding protein (RBP)-RNA interaction (PRI) sites at single nucleotide resolution across the entire transcriptome. The methods disclosed herein recapitulates PRI profiles obtained with several distinct conventional PRI methods in a single assay at efficiencies that are improved by orders of magnitude, and permit the identification of the specific RBP bound at a PRI.
Absstract of: US20260266805A1
0000 A method of analyzing internal components of an organism, the method comprising a) taking an image of internal components of the organism, while said internal components are contained in vivo, and b) analyzing the internal components. Also a method of determining toxicity or efficacy of a substance, the method comprising: a. exposing an organism to one or more substances of interest; b. taking one or more images of one or more internal components of the organism, c. analyzing internal components of the organism from the images to determine the effects of the substance on the organism, and; d. using the results of the analysis to determine the toxicity or efficacy of the one or more substances.
Absstract of: US20260266810A1
The present invention provides a method for detecting two or more analytes in a sample, the method comprising steps (i)-(v). Thus, the present invention provides a method for detecting two or more analytes in a sample in which only the reporter reagents in the vicinity of the surface of the substrate results in a signal, the signal being a local region of the optical component in the second optical state. It is the set of local regions of the optical component in the second optical state that are detected.
Absstract of: US20260266811A1
The present invention relates to a method for detecting an analyte in a sample suitable for detecting the analyte over a range of concentrations, the method comprising steps (i)-(v). Thus, the present invention provides a method for detecting an analyte in a sample in which only the reporter reagents in the vicinity of the surface of the substrate results in a signal, the signal being a local region of the optical component in the second optical state. It is the set of local regions of the optical component in the second optical state that are detected.
Absstract of: WO2025093893A1
The present invention relates to methods of measuring the presence and/or levels of a combination of five biomarkers in a sample, said biomarkers being neurofilament light (NfL) polypeptide, glial fibrillary acidic protein (GFAP), β-Amyloid 1-42 (Aβ1-42), β-Amyloid 1-40 (Aβ1-40), and phosphorylated Tau (p-Tau181, pTau-231 and/or p-Tau217). The methods can be used to predict the subject's risk or likelihood of having and/or developing Alzheimer's disease, thus also provided is a method of predicting a subject's risk or likelihood of having and/or developing Alzheimer's disease, said method comprising measuring the presence of and/or the levels of the combination of five biomarkers. Further provided is a method of prognosing or diagnosing Alzheimer's disease in a subject comprising the methods of measuring the presence of and/or the levels of the combination of five biomarkers, and a method of treating Alzheimer's disease comprising predicting a subject's risk or likelihood of developing or having Alzheimer's disease using the methods of measuring the presence and/or levels of the combination of five biomarkers and administering a treatment if the risk or likelihood exceeds a threshold value.
Absstract of: EP4803610A1
The present invention relates to a biohybrid robot comprising an eye/brain organoid, a motor neuron spheroid and a muscle bundle, and a method for fabricating the same, and a versatile biohybrid robot according to the present invention may cause movement of muscle cells by an electrophysiological signal generated from the eye/brain organoid like a human motor system using light stimulation and a neurotransmitter. It is expected to be utilized in disease models that stimulate human signal transduction systems by combining various neurodegenerative disease models, such as Parkinson's and Alzheimer's disease models, with eye tumor models in the future, and be utilized in the fabrication of drug screening platforms using the operation of versatile biohybrid robots composed of biological tissues.
Absstract of: JP2026144588A
【課題】中枢神経系の抗炎症剤、神経炎症を伴う中枢神経系疾患の治療剤及び神経炎症を伴う中枢神経系疾患の治療剤のスクリーニング方法の提供。【解決手段】セラミドキナーゼの機能を阻害する化合物を有効成分として含む、中枢神経系の抗炎症剤又は神経炎症を伴う中枢神経系疾患の治療剤であって、前記化合物は、セラミドキナーゼ遺伝子の発現を抑制する又はセラミドキナーゼタンパク質の活性を阻害する化合物である抗炎症剤。【選択図】なし
Absstract of: EP4804206A1
The present invention relates to a next generation sequencing (NGS) method for disease prediction through analysis of nail-derived germline mutations and somatic mutations, and a system therefor. Specifically, the present invention relates to a nail-based NGS analysis method for predicting or diagnosing a disease, comprising the steps of: isolating gDNA from nails; and analyzing the isolated gDNA using NGS.
Absstract of: WO2021176336A1
The present disclosure relates to a method of treating a disease or disorder associated with an abnormality in CNS function. Also provided is a method for diagnosing and/or identifying a subject having an abnormality in CNS function. FAM19A1 antagonists that can be used with the present disclosures are also provided.
Nº publicación: JP2026143531A 08/09/2026
Applicant:
ロングエバーオンインコーポレイテッド
Absstract of: AU2021340971A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function.
BOPI
Electronic site
